Indicator of arteriosclerosis in patients with COPD
|
|
- Merryl Lambert
- 5 years ago
- Views:
Transcription
1 ORIGINAL ARTICLES Indicator of arteriosclerosis in patients with COPD Akinori Ebihara 1 Akifumi Watanabe 2 Asuka Nagai 1 Rurika Hamanaka 3 Naoko Imamura 3 Chizumi Yamada 4 Tokuzen Iwamoto 1 Ichiro Kuwahira 1 1 Pulmonary Medicine, Tokai University Tokyo Hospital 2 Erimo Town Clinic 3 General Thoracic Surgery, Tokai University Tokyo Hospital 4 Internal Medicine, Tokai University Tokyo Hospital ABSTRACT Background Cardiovascular events are important comorbidities and complications of chronic obstructive pulmonary disease (COPD). We analyzed data on the maximum intima media thickness (max-imt), the ratio of serum eicosapentaenoic acid to arachidonic acid (EPA/AA), and the Ankle Brachial Pressure Index (ABI) to determine whether there are any correlations among these parameters. Methods A total of 149 subjects (84 men, 65 women) were enrolled in the study between May, 2007 and January, 2014 at the Erimo town clinic in Hokkaido after providing their informed consent. Potential subjects were divided into two groups: Group 1 (G1) had a history of COPD and moderate to severe exposure to tobacco smoke, and a Brinkman Index>400; Group 2 (G2) had a history of other diseases without COPD, such as diabetes, hypertension, and hyperlipidemia. Results G1 included 73 subjects (47 men, 26 women) and G2 included 76 subjects (37 men, 39 women). The max-imt was1.49±0.83 mm for G1 and 1.36±0.68 mm for G2, the ABI values were 0.81±0.48 and 0.91±0.21, and the EPA/AA values 0.41±0.13 and 0.47±0.16, respectively. The Max-IMT of G1 was thus significantly larger than that of G2, and the ABI of G1 was significantly lower than that of G2. There was no significant difference in EPA/AA between G1 and G2. Conclusion In COPD patients with moderate to severe exposure to smoke, a significant increase in max-imt and decrease in ABI were observed. The results of the present study suggest that COPD patients are at increased risk of smoke-related cardiovascular diseases such as acute myocardial infarction and stroke. However, the EPA/AA ratio might not be a good biomarker for assessing cardiovascular risks in COPD. (HEP. 2014; 41: ) Key words Intima Media Thickness (IMT), Eicosapentaenoic Acid (EPA), Arachidonic Acid(AA), EPA/AA, Ankle Brachial Pressure Index(ABI), Tobacco Smoke, COPD. Introduction Chronic obstructive pulmonary disease (COPD) is one of the leading causes of mortality and morbidity worldwide 1, 2). Although COPD has been regarded as a respiratory disease for many years, the multisystemic nature of the disease, which presents with comorbidities such as diabetes mellitus and cardiovascular diseases, is currently an area of interest. Whether these comorbidities are related to risk factors such as smoking, aging, and genetic predisposition has yet to be elucidated 3). Patients with COPD are at increased risk of cardiovascular morbidity and mortality 1). Accumulated evidence has shown a close association between COPD and cardiovascular diseases, especially coronary artery disease 3). In the literature, tobacco smoking has been identified as a causal connection between COPD and coronary artery disease. However, recent epidemiologic studies have shown that systemic inflammation plays a significant role in both atherogenesis and COPD 4). Received: May 14, 2014, Accepted: June 4, Address; Tokai University Tokyo Hospital Yoyogi, Shibuya-ku Tokyo , Japan TEL: , FAX: akinoriebihara@hotmail.com A reduced ratio of plasma eicosapentaenoic acid to arachidonic acid (EPA/AA) is a newly recognized atherosclerotic risk factor. However, this ratio has not been fully investigated in peripheral artery disease 5). A lower EPA concentration is a significant risk factor for ischemic stroke, as are a lower body mass index, lower high-density lipoprotein cholesterol, and smoking. A lower EPA/ AA ratio and a lower body mass index are also significant risk factors for myocardial infarction 6). Recently, Itakura et al. reported in the Japan EPA Lipid Intervention Study (JELIS) that the risk of major coronary events was significantly decreased in individuals with high plasma EPA concentrations compared with those with low concentrations 7). There is a trend toward utilization of the plasma EPA/AA ratio as a new risk marker for cardiovascular disease 8, 9). Carotid artery intima media thickness (IMT) is associated with cardiovascular risk factors and prevalent cardiovascular disease, and is predictive of cardiovascular events 9-11). We have previously reported that early exposure to tobacco smoke significantly increases the prevalence of COPD 12). As a follow up, we hypothesized that COPD resulting from early exposure to tobacco smoke may cause an increase in IMT that correlates with the increase in the prevalence of smoke-related vascular comorbidities such as cardiovascular and cerebrovascular diseases. Peripheral artery disease can be diagnosed and quantified by 16 (528)
2 Ebihara et al.: Indicator of arteriosclerosis in COPD means of the Ankle Brachial Pressure Index (ABI), which compares the systolic pressure at the ankle with the systolic pressure in the arm 10). In the present study, we analyzed the max-imt, EPA/AA ratio, and ABI to determine whether there were any correlations among them. 1. Materials and Methods A total of 149 subjects (84 men, 65 women) were enrolled in the study between May, 2007 and January, 2014 at the Erimo town clinic in Hokkaido. All provided their informed consent (Table 1). The patients underwent spirometry (GRAPH junior HI-101: Chest, Inc. Japan) and completed a self-report questionnaire on their clinical history and COPD risk factors including exposure to tobacco smoke and age of smoking initiation. COPD was diagnosed using the Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines 13). Because we were unable to perform airway reversibility testing, we used the following four questions on the questionnaire in the same order as in the NICE study 14) : (1) During the past 12 months have you had more than one episode of waking at night or early in the morning as a result of spasmodic breathlessness even when you did not have a cold? (2) During the past 12 months have you had more than one episode of waking at night or early in the morning as a result of wheezing or whistling in the chest even when you did not have a cold? (3) Have you ever been told by a doctor that you had bronchial asthma? (4) Were you ever diagnosed as having asthma during your childhood? An affirmative response to any combination of these questions defined the patient as having possible asthma. The remainder of the patients with airflow limitation were considered to have COPD 14). Stage category was classified according to airflow limitation (%FEV 1 ) in accordance with the GOLD classification. Stage I included mild airflow limitation (%FEV 1 80%), Stage II moderate flow limitation (50% %FEV 1 <80%), Stage III severe flow limitation (30% %FEV 1 <50%), and Stage IV very severe flow limitation (%FEV 1 <30%) 13). We defined moderate and severe smoking as a value>400 on the Brinkman Index (B.I.). The B.I is based on the number of cigarettes smoked per day as well as the number of years of smoking. For example, a B.I of 400 indicates a person who smoked 20 cigarettes per day for 20 years. We divided the potential subjects into two groups: G1) Group 1 had a history of COPD with complications, severe and moderate exposure to tobacco smoke, and a B.I>400. G2) Group 2 had a history of diseases such as diabetes, hypertension, and hyperlipidemia without COPD, severe and moderate exposure to tobacco smoke, and a B.I>400. AA and EPA were measured from a fasting venous blood sample collected in the morning. After plasma separation, AA and EPA were determined in the SRL in Sapporo. ABI was determined as follows: ABI was defined as the highest of two measurements of ankle systolic pressure divided by brachial pressure in the arms 15). An ABI of 0.9 was considered diagnostic. Statistical analyses were performed using SPSS v19.0 (SPSS, Inc.). Analyses were performed using an unpaired t test for continuous variables and the χ 2 test for categorical variables. The standard P<0.05 significance level was used for these tests. All values in the text and tables are given as the mean±sd. 2. Results Table 1 shows the characteristics of the patients in the present Table 1 Patients Characteristics G1 (n=73) G2 (n=76) COPD with complications Disease without COPD Gender (male) Age 76±4 72±8 B.I 657±163* 472±263* DM 7* 13* HTN HL 9 6 DM+HTN 7* 12* DM+HL 5 5 HTN+HL 5 5 DM+HTN+HL (*P<0.05) Group 1 had a history of COPD with complications. Group 2 had a history of other diseases, such as diabetes, hypertension, and hyperlipidemia without COPD. Data are the number of patients or mean±sd. B.I; Brinkman Index, DM; Diabetes mellitus, HTN; Hypertension, HL; Hyperlipidemia. There were significant differences in the complication rate of diabetes and smoking status (Brinkman Index) between G1 and G2. Brinkman Index is significantly higher in G1 than in G2. Diabetes is significantly lower in G1 than in G2. (529) 17
3 Fig. 1 Rate of complications in each group Fig. 1 shows the rate of complications in each group. Hypertension is the most common complications in each group. Rate of diabetes in the G2 is higher than G1. Fig. 2 The GOLD Stage in Group 1 Fig. 2 shows the GOLD stage in Group 1. GOLD stage II is the highest among all stages. Fig. 3 Max-IMT in each group G1 had significantly higher max-imt than G2. study. G1 included 73 subjects (47 men, 26 women, mean age 76±4 years) and G2 included 76 subjects (37 men, 39 women, mean age 72±8 years). The number and percentage of complications in each group are shown in Table 1 and Fig. 1: G1 (diabetes: 7 subjects, 9.6%; hypertension: 23 subjects, 31.5%; hyperlipidemia: 9 subjects, 12.4%; other complications: 30 subjects, 41.1%); G2 (diabetes: 32 subjects, 42.1%; hypertension: 48 subjects, 63.2%; hyperlipidemia: 29 subjects, 38.2%; other complications: 33 subjects, 43.4%). The most common complication was hypertension (G1: 23 subjects, 31.5% vs. G2: 48 subjects, 63.2%). G1 had a much higher B.I than G2 (G1: 657±163, G2: 472±263) (Table 1). There were significant differences in the complication rate of diabetes and smoking status (Brinkman Index) between G1 and G2. Brinkman Index is significantly higher in G1 than in G2. Diabetes is significantly lower in G1 than in G2. Because max- IMT and ABI which are the marker of arteriosclerosis, are significantly different between the two groups, the results suggest COPD rather than diabetes would promote arteriosclerosis further. Figure 2 shows the GOLD stage in each group. G1 had 14 subjects in stage I, 35 subjects in stage II, 15 subjects in stage III, and 9 subjects in stage IV. GOLD stage II was the most common category. There was no significant difference in the EPA/AA, max-imt and ABI in the GOLD Stage I/II and the GOLD Stage III/IV. The present results suggest that smoking may promote arteriosclerosis in all stages of COPD, resulting in an increase in the cardiovascular events. The max-imt values in G1 and G2 were 1.49±0.83 mm and 1.36±0.68 mm, respectively. G1 had a significantly higher max- IMT than G2 (Fig. 3). The ABI (0.9<ABI<1.3) was 0.81±0.48 in G1 and 0.91± 0.21 in G2. The mean EPA concentration was 74.5±23.5 μg/ml in G1 and 56.3±22.4 in G2. The mean AA concentration was 132.9±24.9 μg/ml in G1 and 118.2±38.5 μg/ml in G2. The EPA/ AA ratio was 0.56±0.13 in G1 and 0.48±0.16 in G2 (Table 2). There was no significant difference in EPA/AA between G1 and G2. However, G1 had lower ABI ratio values than G2 (Fig. 4). There was a significant correlation between max-imt and ABI. However, there was no correlation between max-imt and EPA/AA, and ABI and EPA/AA (Fig. 5). Table 2 EPA/AA ratio, ABI, Max-IMT, EPA, and AA in each group G1 EPA/AA 0.56± ±0.16 Max-IMT(mm) 1.49±0.83* 1.36±0.68* EPA (μg/ml) 74.5± ±22.4 AA (μg/ml) 132.9± ±38.5 (*P<0.05) EPA (Eicosapentaenoic Acid):11.6~107.2, ABI (ankle brachial index): 0.9<ABI<1.3, EPA/ AA ratio: 0.11~0.50, AA (Arachidonic Acid): 85.1~207.8 G2 18 (530)
4 Ebihara et al.: Indicator of arteriosclerosis in COPD Fig. 4 EPA/AA and ABI in each group There was no significant difference in EPA/AA between G1 and G2. G1 had lower ABI values than G2. Fig. 5 There was a significant correlation between max-imt and ABI 3. Discussion The World Health Organization (WHO) has predicted that COPD will become the fifth largest disease burden and the third greatest cause of death by ). Because COPD is not usually detected until patients seek medical attention for dyspnea or exacerbation 17), COPD is under-diagnosed and available prevalence and mortality data are thus likely to be greatly underestimated by healthcare providers. There is, therefore, a need to improve our diagnostic and therapeutic options for such a devastating disease. In a multiple logistic regression analysis in a previous study, a lower EPA concentration was identified as a significant risk factor for myocardial infarction, as were a lower body mass index, lower high-density lipoprotein cholesterol, and smoking. In the analysis of subtypes, a lower EPA/AA ratio and a lower body mass index were identified as significant risk factors for myocardial infarction 18). However, large-artery atherosclerosis was not related to the EPA concentration or the EPA/AA ratio. The risk of coronary artery disease thus appears to be influenced by variations in plasma fatty acid composition. Traditional cardiovascular risk factors are common in COPD. It has been reported that there is an increased prevalence of diabetes and hypertension in patients with COPD compared with healthy individuals, and this increased prevalence was even more evident in GOLD stages III and IV in the Atherosclerosis Risk in Communities Study population 19). The vascular risk in COPD is less likely to be attributed to an atherogenic lipid pattern 20). In the present study, there was thickening of the IMT and a decrease in ABI that was significant in patients that had both COPD and complications such as diabetes or hypertension. However, there was no significant difference in the EPA/AA ratio. One reason for this could be that the mechanisms mediating arteriosclerosis are different between COPD and dyslipidemia. In particular, chronic inflammation associated with COPD could produce thickening of the vascular endothelium by calcification and fibrosis, which may result in a significant change in ABI and IMT. However, in this instance, and unlike the case with an abnormal metabolism such as diabetes, the EPA/AA ratio might not be affected by the chronic inflammation induced by COPD. These findings suggest that the EPA/AA ratio might not be a good biomarker in COPD. There are several limitations to the present study. First, we studied a relatively small number of patients with COPD. Second, all of the patients in the COPD group were receiving regular treatment with inhaled bronchodilators and/or steroids, and some subjects in both groups were on antihyperlipidemic agents, which may have been a factor that mitigated the impact of EPA/AA and ABI atherosclerosis. We did not investigate whether these agents had any effect on the study variables. Acknowledgements The authors wish to thank staff of Erimo town clinic and Health Division of Erimo Town. This study was funded by grant from the Japan Society of Health Evaluation and Promotion, and Grants-in-Aid for Scientific Research (No ). The authors state that they have no Conflict of Interest (COI). REFERENCES 1) John D, William M: Cardiovascular disease in COPD. Chest: 143: , ) Johonston A, Mannino D, Hagan G, et al.: Relationship between lung function impairment and incidence or recurrence of cardiovascular events in a middle-age cohort. Thorax: 63: , ) Dyerberg J, Bang H, Stoffersen E, et al.: Eicosapentaenoic acid and prevention of thrombosis and atherosclerosis? Lancet: 2: , ) Mannino D, Doherty D, Sonia Buist A: Global Initiative on obstructive lung disease (GOLD) classification of lung disease and mortality: finding from the atherisclerosis. Risk in communities (ARIC) study. Respir Med: 100: , ) Ikeya Y, Fukuyama N, Kitajima W, et al.: Comparison of eicosapentaenoic acid concentrations in plasma between patients with ischemic stroke and control subjects. Nutrition: 29: , ) Bang H, Dyerberg J, Sinclair H. et al.: The composition of the Eskimo food in north western Greenland. Am J Clin Nutr: 33: , ) Itakura, M. Yokoyama, M. Matsuzaki, et al.: Relationships (531) 19
5 between plasma fatty acid composition and coronary artery disease. J Atheroscler Thromb: 18: , ) Kashiyama T, Ueda Y, Nemoto T, et al.: Relationship between coronary plaque vulnerability and serum n-3/n-6 polyunsaturated fatty acid ratio. Circ J: 75: , ) Domei T, Yokoi H, Kuramitsu S, et al.: Ratio of serum n-3 to n-6 polyunsaturated fatty acids and the incidence of major adverse cardiac events in patients undergoing percutaneous coronary intervention. Circ J: 76: , ) Tendera M, Aboyans V, Bartelink M, et al.: ESC Guidelines on the diagnosis and treatment of peripheral artery diseases: document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries. The task force on the diagnosis and treatment of peripheral artery diseases of the European society of cardiology (ESC). Eur Heart J: 32: , ) Norgren L, Hiatt WR, Dormandy JA, et al.: Inter-society consensus for the management of peripheral arterial disease. Int Angiol: 26: , ) Ebihara A, Nagai A, Nakano T, Iwamoto T, Kuwahira I: The Influence of Early Exposure to Tobacco Smoke for Pulmonary Disease One town model from Erimo, Japan. Health Evaluation and Promotion: 39: , ) Global Initiative for chronic obstructive lung disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. (Updated 2010): 14) Fukuchi Y, Nishimura M, Ichinose M, et al.: COPD in Japan: the Nippon COPD epidemiology study. Respirology: 9: , ) National Institute of Clinical Excellence: Lower Limb Peripheral Arterial Disease: Full Guideline CG147. London: National Clinical Guidance Centre, ) Murray. C, Lopez. A: Alternative projections of mortality and disability by cause : Global Burden of Disease Study. Lancet: 349: , ) Shivanthan M, Rajapakse S: Magnesium for acute exacerbation of chronic obstructive pulmonary disease: A systematic review of randomised trials. Ann Thorac Med: 9: 77-80, ) Fujihara M, Fukata M, Odashiro K, et al.: Reduced plasma eicosapentaenoic acid-arachidonic acid ratio in peripheral artery disease. Angiology: 64: , ) Mannino D, Thorn D, Swensen A, et al.: Prevalence and outcomes of diabetes, hypertension and cardiovascular disease in COPD. Eur Respir J: 32: , ) Basili S, Ferroni P, Vieri M, et al.: Lipoprotein serum levels in patientsaffected by chronic obstructive pulmonary disease. Atherosclerosis: 147: , (532)
HDL-C. J Jpn Coll Angiol, 2008, 48: NIPPON DATA80, MEGA study, JELIS, dyslipidemia, risk assessment chart
Online publication March 25, 2009 48 6 2007 2007 HDL-C LDL-C HDL-C J Jpn Coll Angiol, 2008, 48: 463 470 NIPPON DATA80, MEGA study, JELIS, dyslipidemia, risk assessment chart 1987 NIPPON DATA80 Iso 10 MRFIT
More informationThis is a cross-sectional analysis of the National Health and Nutrition Examination
SUPPLEMENTAL METHODS Study Design and Setting This is a cross-sectional analysis of the National Health and Nutrition Examination Survey (NHANES) data 2007-2008, 2009-2010, and 2011-2012. The NHANES is
More informationThe Impact of Smoking on Acute Ischemic Stroke
Smoking The Impact of Smoking on Acute Ischemic Stroke Wei-Chieh Weng, M.D. Department of Neurology, Chang-Gung Memorial Hospital, Kee-Lung, Taiwan Smoking related mortality Atherosclerotic vascular disease
More informationAmerican Thoracic Society (ATS) Perspective
National Surveillance System for Chronic Lung Disease (CLD): American Thoracic Society (ATS) Perspective Gerard J. Criner, M.D. Chronic Obstructive Pulmonary Disease (COPD) l Definition: Group of chronic
More informationThe clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall
More informationAsthma COPD Overlap (ACO)
Asthma COPD Overlap (ACO) Dr Thomas Brown Consultant Respiratory Physician Thomas.Brown@porthosp.nhs.uk Dr Hitasha Rupani Consultant Respiratory Physician Hitasha.rupani@porthosp.nhs.uk What is Asthma
More informationPreventive Effects of an EPA Preparation on Restenosis after Carotid Artery Stenting
DOI: 10.5797/jnet.oa.2018-0032 Preventive Effects of an EPA Preparation on Restenosis after Carotid Artery Stenting Tomoo Ohashi, 1 Yusuke Arai, 2 Daichi Kato, 2 Shigeru Aoyagi, 2 Hirofumi Okada, 2 Tomoya
More informationLife-long asthma and its relationship to COPD. Stephen T Holgate School of Medicine University of Southampton
Life-long asthma and its relationship to COPD Stephen T Holgate School of Medicine University of Southampton Definitions COPD is a preventable and treatable disease with some significant extrapulmonary
More informationPULSE WAVE VELOCITY AS A NEW ASSESSMENT TOOL FOR ATHEROSCLEROSIS
PULSE WAVE VELOCITY AS A NEW ASSESSMENT TOOL FOR ATHEROSCLEROSIS Introduction Hirohide Yokokawa, M.D., Ph.D. 1 , Aya Goto, M.D., MPH, Ph.D. 2 , and Seiji Yasumura, M.D., Ph.D.
More informationClinical Features and Subtypes of Ischemic Stroke Associated with Peripheral Arterial Disease
Cronicon OPEN ACCESS EC NEUROLOGY Research Article Clinical Features and Subtypes of Ischemic Stroke Associated with Peripheral Arterial Disease Jin Ok Kim, Hyung-IL Kim, Jae Guk Kim, Hanna Choi, Sung-Yeon
More informationAsthma J45.20 Mild, uncomplicated J45.21 Mild, with (acute) exacerbation J45.22 Mild, with status asthmaticus
A Fib & Flutter I48.0 Paroxysmal atrial fibrillation I48.1 Persistent atrial fibrillation I48.2 Chronic atrial fibrillation I48.3 Typical atrial flutter Asthma J45.20 Mild, uncomplicated J45.21 Mild, with
More informationFEV1 predicts length of stay and in-hospital mortality in patients undergoing cardiac surgery
EUROPEAN SOCIETY OF CARDIOLOGY CONGRESS 2010 FEV1 predicts length of stay and in-hospital mortality in patients undergoing cardiac surgery Nicholas L Mills, David A McAllister, Sarah Wild, John D MacLay,
More informationHeart Failure and COPD: Common Partners, Common Problems. Nat Hawkins Liverpool Heart and Chest Hospital
Heart Failure and COPD: Common Partners, Common Problems Nat Hawkins Liverpool Heart and Chest Hospital Disclosures: No conflicts of interest Common partners, common problems COPD in HF common partners
More informationReduced lung function in midlife and cognitive impairment in the elderly
Page 1 of 5 Reduced lung function in midlife and cognitive impairment in the elderly Giuseppe Verlato, M.D. Ph.D Department of Diagnostics and Public Health University of Verona Verona, Italy Mario Olivieri,
More informationRespiratory diseases in Ostrołęka County
Respiratory diseases in Ostrołęka County 4400 persons underwent examination 950 persons were given referrals to more detailed investigation 600 persons were examined so far The results of more detailed
More informationRelationship of Atherosclerotic Risk Factors with Pulmonary Age and Vascular Age. Masao Shimizu, Asako Okano, Masaki Adachi, Yoshiaki Maruyama
Original Article 0000 ; 6 : 00 00 Relationship of Atherosclerotic Risk Factors with Pulmonary Age and Vascular Age Masao Shimizu, Asako Okano, Masaki Adachi, Yoshiaki Maruyama Abstract Background: Different
More informationCOPD as a comorbidity of heart failure in elderly patients
COPD as a comorbidity of heart failure in elderly patients Professor Mitja Lainscak, MD, PhD, FESC, FHFA Departments of Cardiology and Research&Education, General Hospital Celje Faculty of Medicine, University
More informationCardiovascular and Respiratory Disorders
Cardiovascular and Respiratory Disorders Blood Pressure Normal blood pressure is 120/80 mmhg (millimeters of mercury) Hypertension is when the resting blood pressure is too high Systolic BP is 140 mmhg
More informationCOMORBIDITIES AS AN ELEMENT OF MULTIDIMENSIONAL PROGNOSTIC ASSESSMENT OF PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE
JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY 2008, 59, Suppl 6, 297 301 www.jpp.krakow.pl M. GRABICKI 1, H. PARYSEK 1, H. BATURA-GABRYEL 1, I. BRODNICKA 2 COMORBIDITIES AS AN ELEMENT OF MULTIDIMENSIONAL PROGNOSTIC
More informationUpdate on Lipid Management in Cardiovascular Disease: How to Understand and Implement the New ACC/AHA Guidelines
Update on Lipid Management in Cardiovascular Disease: How to Understand and Implement the New ACC/AHA Guidelines Paul Mahoney, MD Sentara Cardiology Specialists Lipid Management in Cardiovascular Disease
More informationIntroduction. Risk factors of PVD 5/8/2017
PATHOPHYSIOLOGY AND CLINICAL FEATURES OF PERIPHERAL VASCULAR DISEASE Dr. Muhamad Zabidi Ahmad Radiologist and Section Chief, Radiology, Oncology and Nuclear Medicine Section, Advanced Medical and Dental
More informationStep-down approach in chronic stable asthma: A comparison of reducing dose Inhaled Formoterol/ Budesonide with maintaining Inhaled Budesonide.
Step-down approach in chronic stable asthma: A comparison of reducing dose Inhaled Formoterol/ Budesonide with maintaining Inhaled Budesonide. By: DR MOHD SHAMSUL AMRI Supervisor: Associate Professor Dr
More informationLandmark Phase III Study of Bayer s Xarelto (Rivaroxaban) Initiated for the Secondary Prevention of Myo
Xarelto (Rivaroxaban) Landmark Phase III Study of Bayer s Xarelto (Rivaroxaban) Initiated for the Secondary Prevention of Myocardial Infarction and Death in Patients with Coronary or Peripheral Artery
More informationDifferential diagnosis
Differential diagnosis The onset of COPD is insidious. Pathological changes may begin years before symptoms appear. The major differential diagnosis is asthma, and in some cases, a clear distinction between
More informationCOPD, Asthma, Or Something In Between? Sharon R. Rosenberg Assistant Professor of Medicine Northwestern University December 4, 2013
COPD, Asthma, Or Something In Between? Sharon R. Rosenberg Assistant Professor of Medicine Northwestern University December 4, 2013 None Disclosures Definitions Asthma Asthma is a chronic inflammatory
More informationIntermediate Methods in Epidemiology Exercise No. 4 - Passive smoking and atherosclerosis
Intermediate Methods in Epidemiology 2008 Exercise No. 4 - Passive smoking and atherosclerosis The purpose of this exercise is to allow students to recapitulate issues discussed throughout the course which
More informationUNDERSTANDING COPD MEDIA BACKGROUNDER
UNDERSTANDING COPD MEDIA BACKGROUNDER What is COPD? Chronic Obstructive Pulmonary Disease (COPD) also called emphysema and/or chronic obstructive bronchitis* is a preventable lung disease caused by the
More informationJoshua A. Beckman, MD. Brigham and Women s Hospital
Peripheral Vascular Disease: Overview, Peripheral Arterial Obstructive Disease, Carotid Artery Disease, and Renovascular Disease as a Surrogate for Coronary Artery Disease Joshua A. Beckman, MD Brigham
More informationPrevalence of Chronic Obstructive Pulmonary Disease in Japanese People on Medical Check-Up
Tohoku J. Exp. Med., 2005, 207, Prevalence 41-50 of COPD on Medical Check-Up 41 Prevalence of Chronic Obstructive Pulmonary Disease in Japanese People on Medical Check-Up HIDEKAZU TAKEMURA, WATARU HIDA,
More informationArteriosclerosis & Atherosclerosis
Arteriosclerosis & Atherosclerosis Arteriosclerosis = hardening of arteries = arterial wall thickening + loss of elasticity 3 types: -Arteriolosclerosis -Monckeberg medial sclerosis -Atherosclerosis Arteriosclerosis,
More informationBayer Pharma AG Berlin Germany Tel News Release. Not intended for U.S. and UK Media
News Release Not intended for U.S. and UK Media Bayer Pharma AG 13342 Berlin Germany Tel. +49 30 468-1111 www.bayerpharma.com Landmark Phase III Study of Bayer s Xarelto (Rivaroxaban) Initiated for the
More informationASTHMA-COPD OVERLAP SYNDROME 2018: What s All the Fuss?
ASTHMA-COPD OVERLAP SYNDROME 2018: What s All the Fuss? Randall W. Brown, MD MPH AE-C Association of Asthma Educators Annual Conference July 20, 2018 Phoenix, Arizona FACULTY/DISCLOSURES Randall Brown,
More informationHow would you manage Ms. Gold
How would you manage Ms. Gold 32 yo Asian woman with dyslipidemia Current medications: Simvastatin 20mg QD Most recent lipid profile: TC = 246, TG = 100, LDL = 176, HDL = 50 What about Mr. Williams? 56
More informationIs there an association between atherosclerosis and chronic venous disease?
Is there an association between atherosclerosis and chronic venous disease? Karel Roztocil, IKEM, Praha Hungarian Society of Angiology and Vascular Surgery Congress, Szombathely 2017 Disclosure Nothing
More informationCOPD: early detection, screening and case-finding: what is the evidence? Prof. Jan-Willem Lammers, Md PhD Department of Respiratory Diseases
COPD: early detection, screening and case-finding: what is the evidence? Prof. Jan-Willem Lammers, Md PhD Department of Respiratory Diseases «If you test one smoker with cough every day You will diagnose
More informationBecause we care about your health
Contact us For information on Trust services see www.awp.nhs.uk PALS To make a comment, raise a concern or make a complaint, please contact the Trust s Patient Advice and Liaison Service (PALS). Smoking
More informationMEDICAL POLICY SUBJECT: CORONARY CALCIUM SCORING
MEDICAL POLICY PAGE: 1 OF: 5 If the member's subscriber contract excludes coverage for a specific service it is not covered under that contract. In such cases, medical policy criteria are not applied.
More informationSGRQ Questionnaire assessing respiratory disease-specific quality of life. Questionnaire assessing general quality of life
SUPPLEMENTARY MATERIAL e-table 1: Outcomes studied in present analysis. Outcome Abbreviation Definition Nature of data, direction indicating adverse effect (continuous only) Clinical outcomes- subjective
More informationCOPD Bronchiectasis Overlap Syndrome.
COPD Bronchiectasis Overlap Syndrome. John R Hurst 1, J Stuart Elborn 2, and Anthony De Soyza 3 on Behalf of the BRONCH-UK Consortium (D Bilton, J Bradley, JS Brown, J Duckers, F Copeland, A Floto, J Foweraker,
More informationProductivity losses in chronic obstructive pulmonary disease a population-based survey.
Online supplement to Productivity losses in chronic obstructive pulmonary disease a population-based survey. Running head: Productivity losses in COPD. Authors: Marta Erdal, Department of Thoracic Medicine,
More informationCoronary artery disease (CAD) risk factors
Background Coronary artery disease (CAD) risk factors CAD Risk factors Hypertension Insulin resistance /diabetes Dyslipidemia Smoking /Obesity Male gender/ Old age Atherosclerosis Arterial stiffness precedes
More informationOutline FEF Reduced FEF25-75 in asthma. What does it mean and what are the clinical implications?
Reduced FEF25-75 in asthma. What does it mean and what are the clinical implications? Fernando Holguin MD MPH Director, Asthma Clinical & Research Program Center for lungs and Breathing University of Colorado
More informationAsthma and COPD in older people lumping or splitting? Christine Jenkins Concord Hospital Woolcock Institute of Medical Research
Asthma and COPD in older people lumping or splitting? Christine Jenkins Concord Hospital Woolcock Institute of Medical Research Concord Hospital Woolcock Institute of Medical Research Joe has asthma What
More informationLow fractional diastolic pressure in the ascending aorta increased the risk of coronary heart disease
(2002) 16, 837 841 & 2002 Nature Publishing Group All rights reserved 0950-9240/02 $25.00 www.nature.com/jhh ORIGINAL ARTICLE Low fractional diastolic pressure in the ascending aorta increased the risk
More informationCourse Handouts & Disclosure
COPD: Disease Trajectory and Hospice Eligibility Terri L. Maxwell PhD, APRN VP, Strategic Initiatives Weatherbee Resources Hospice Education Network Course Handouts & Disclosure To download presentation
More informationPulmonary Function Testing: Concepts and Clinical Applications. Potential Conflict Of Interest. Objectives. Rationale: Why Test?
Pulmonary Function Testing: Concepts and Clinical Applications David M Systrom, MD Potential Conflict Of Interest Nothing to disclose pertinent to this presentation BRIGHAM AND WOMEN S HOSPITAL Harvard
More informationRESPIRATORY CARE IN GENERAL PRACTICE
RESPIRATORY CARE IN GENERAL PRACTICE Definitions of Asthma and COPD Asthma is due to inflammation of the air passages in the lungs and affects the sensitivity of the nerve endings in the airways so they
More informationPathway diagrams Annex F
Pathway diagrams Annex F Fig 1 Asthma: The patient journey Asthma is diagnosed Making the diagnosis of asthma Confirming the diagnosis may depend on history, response to treatment, measurement of airflow
More informationChronic Obstructive Pulmonary Disease (COPD).
Chronic Obstructive Pulmonary Disease (COPD). Linde: Living healthcare 02 03 Chronic Obstructive Pulmonary Disease (COPD). A pocket guide for healthcare professionals. COPD the facts Moderate to severe
More informationOnline Data Supplement. Prevalence of Chronic Obstructive Pulmonary Disease in Korea: Results of a Population-based Spirometry Survey
Online Data Supplement Prevalence of Chronic Obstructive Pulmonary Disease in Korea: Results of a Population-based Spirometry Survey Dong Soon Kim, MD, Young Sam Kim MD, Kee Suk Chung MD, Jung Hyun Chang
More informationDUKECATHR Dataset Dictionary
DUKECATHR Dataset Dictionary Version of DUKECATH dataset for educational use that has been modified to be unsuitable for clinical research or publication (Created Date and Time: 28OCT16 14:35) Table of
More informationMorbidity and mortality associated with the restrictive spirometric pattern: a longitudinal study
< Supplementary data are published online only. To view these files please visit the journal online (http://thorax.bmj. com). 1 Arizona Respiratory Center, University of Arizona, Tucson, Arizona, USA 2
More informationThe presenter does not have any potential conflicts of interest to disclose
Carotid intima-media thickness as a predictor of multi territory atherosclerotic occlusive disease in patients with symptomatic subclavian artery obstruction Leszek Wrotniak 1, Anna Kabłak Ziembicka 1,
More informationANNUAL FOLLOW-UP QUESTIONNAIRE
SLEEP HEART HEALTH STUDY - TUCSON ANNUAL FOLLOW-UP QUESTIONNAIRE - 2003 Dear Sleep Heart Health Study participant: Today s Date: / / Month Day Year Please take the time to complete and return this short
More informationBurden of major Respiratory Diseases
Burden of major Respiratory Diseases WHO Survey Ryazan region of Russia, Ryazan region of Russia, health care system: 104 hospitals district hospitals 32 rural hospitals 44 65 out-patient departments
More informationIntima-Media Thickness
European Society of Cardiology Stockholm, 30th August 2010 Intima-Media Thickness Integration of arterial assessment into clinical practice Prof Arno Schmidt-Trucksäss, MD Institute of Exercise and Health
More informationCLINICAL OUTCOME Vs SURROGATE MARKER
CLINICAL OUTCOME Vs SURROGATE MARKER Statin Real Experience Dr. Mostafa Sherif Senior Medical Manager Pfizer Egypt & Sudan Objective Difference between Clinical outcome and surrogate marker Proper Clinical
More informationHow to treat COPD? What is the mechanism of dyspnea? Smoking cessation
: The Increasing Role of the FP Alan Kaplan, MD, CCFP(EM) Presented at the Primary Care Today: Education Conference and Medical Exposition, Toronto, Ontario, May 2006. Chronic obstructive pulmonary disease
More informationLnformation Coverage Guidance
Lnformation Coverage Guidance Coverage Indications, Limitations, and/or Medical Necessity Abstract: B-type natriuretic peptide (BNP) is a cardiac neurohormone produced mainly in the left ventricle. It
More informationDefining COPD. Georgina Grantham Community Respiratory Team Leader/ Respiratory Nurse Specialist
Defining COPD Georgina Grantham Community Respiratory Team Leader/ Respiratory Nurse Specialist Defining COPD Chronic Obstructive Pulmonary Disease (COPD) is a common, preventable and treatable disease
More informationCardiovascular Mortality: General Population vs ESRD Dialysis Patients
Cardiovascular Mortality: General Population vs ESRD Dialysis Patients Annual CVD Mortality (%) 100 10 1 0.1 0.01 0.001 25-34 35-44 45-54 55-64 66-74 75-84 >85 Age (years) GP Male GP Female GP Black GP
More informationPrevalence of Chronic Obstructive Pulmonary Disease and Tobacco Use in Veterans at Boise Veterans Affairs Medical Center
Prevalence of Chronic Obstructive Pulmonary Disease and Tobacco Use in Veterans at Boise Veterans Affairs Medical Center William H Thompson MD and Sophie St-Hilaire DVM PhD BACKGROUND: Although its prevalence
More informationPulmonary Pearls. Medical Pearls. Case 1: Case 1 (cont.): Case 1: What is the Most Likely Diagnosis? Case 1 (cont.):
Pulmonary Pearls Christopher H. Fanta, MD Pulmonary and Critical Care Division Brigham and Women s Hospital Partners Asthma Center Harvard Medical School Medical Pearls Definition: Medical fact that is
More informationIndication: Treatment: Objectives: Primary Outcome/Efficacy Variable: Secondary Outcome/Efficacy Variable(s): Statistical Methods:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationSupplementary Online Content
Supplementary Online Content Regan EA, Lynch DA, Curran-Everett D, et al; Genetic Epidemiology of COPD (COPDGene) Investigators. Clinical and radiologic disease in smokers with normal spirometry. Published
More informationSydney, AUSTRALIA Beijing, CHINA Hyderabad, INDIA Oxford, UK. Affiliated with
Sydney, AUSTRALIA Beijing, CHINA Hyderabad, INDIA Oxford, UK Affiliated with COPD and Comorbidities Norbert Berend Professor Emeritus University of Sydney Head, Respiratory Research The George Institute
More informationPage 126. Type of Publication: Original Research Paper. Corresponding Author: Dr. Rajesh V., Volume 3 Issue - 4, Page No
ISSN- O: 2458-868X, ISSN P: 2458 8687 Index Copernicus Value: 49. 23 PubMed - National Library of Medicine - ID: 101731606 SJIF Impact Factor: 4.956 International Journal of Medical Science and Innovative
More informationThe study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationAsthma 2015: Establishing and Maintaining Control
Asthma 2015: Establishing and Maintaining Control Webinar for Michigan Center for Clinical Systems Improvement (Mi-CCSI) Karen Meyerson, MSN, APRN, NP-C, AE-C June 16, 2015 Asthma Prevalence Approx. 26
More informationUnderuse of spirometry by general practitioners for the diagnosis of COPD in Italy
Monaldi Arch Chest Dis 2005; 63: 1, 6-12 ORIGINAL ARTICLE Underuse of spirometry by general practitioners for the diagnosis of COPD in Italy G. Caramori 1, G. Bettoncelli 2, R. Tosatto 3, F. Arpinelli
More informationRoflumilast (Daxas) for chronic obstructive pulmonary disease
Roflumilast (Daxas) for chronic obstructive pulmonary disease August 2009 This technology summary is based on information available at the time of research and a limited literature search. It is not intended
More informationAPSR RESPIRATORY UPDATES
APSR RESPIRATORY UPDATES Volume 4, Issue 7 Newsletter Date: July 2012 APSR EDUCATION PUBLICATION Inside this issue: Quantitative imaging of airways Small-Airway Obstruction and Emphysema in Chronic Obstructive
More informationNormal blood vessels A= artery V= vein
Normal blood vessels A= artery V= vein Artery (A) versus vein (V) ARTERIOSCLEROSIS Arteriosclerosis ="hardening of the arteries" arterial wall thickening and loss of elasticity. Three patterns are recognized,
More informationBode index as a predictor of severity in patients with chronic obstructive pulmonary disease.
IOSR Journal of Dental and Medical Sciences (IOSR-JDMS) e-issn: 2279-0853, p-issn: 2279-0861.Volume 15, Issue 5 Ver. VII (May. 2016), PP 93-100 www.iosrjournals.org Bode index as a predictor of severity
More informationSupplementary Online Content
Supplementary Online Content Dharmarajan K, Wang Y, Lin Z, et al. Association of changing hospital readmission rates with mortality rates after hospital discharge. JAMA. doi:10.1001/jama.2017.8444 etable
More informationWhat is Asthma? Chronic disease of the airways that may cause Wheezing Breathlessness Chest tightness Night time or early morning coughing
Asthma What is Asthma? Chronic disease of the airways that may cause Wheezing Breathlessness Chest tightness Night time or early morning coughing Episodes are usually associated with widespread, but
More informationClinical and radiographic predictors of GOLD-Unclassified smokers in COPDGene
Clinical and radiographic predictors of GOLD-Unclassified smokers in COPDGene Emily S. Wan, John E. Hokanson, James R. Murphy, Elizabeth A. Regan, Barry J. Make, David A. Lynch, James D. Crapo, Edwin K.
More informationMEDICAL STUDENT INVOLVEMENT IN ASSESSING RESPIRATORY SYMPTOMS TO IMPROVE EARLY DETECTION OF LUNG DISEASE IN HIV PATIENTS.
MEDICAL STUDENT INVOLVEMENT IN ASSESSING RESPIRATORY SYMPTOMS TO IMPROVE EARLY DETECTION OF LUNG DISEASE IN HIV PATIENTS Simone Neri Definition of COPD COPD, a common preventable and treatable disease,
More informationRelationship between lung function impairment and incidence or recurrence of cardiovascular events in a middle-aged cohort
c Supplementary tables 1 3 are published online only at http:// thorax.bmj.com/content/vol63/ issue7 1 Division of Pulmonary and Critical Care Medicine, University of Kentucky Medical Center, Lexington,
More informationStatins in lung disease
Statins in lung disease Associate Professor Robert Young BMedSc, MBChB, DPhil (Oxon), FRACP, FRCP University of Auckland, New Zealand Smoking and its complications Respiratory COPD Cardiovascular CAD Smoking
More informationAsthma Tutorial. Trainer MRW. Consider the two scenarios, make an attempt at the questions, what guidance have you used?
Registrar: LG PR RS Topic Asthma and COPD Asthma Tutorial Trainer MRW Date of Tutorial 18 th Jan 2007 Objectives of the tutorial How to diagnose What investigations and when Treatment guidelines QoF Criteria
More informationCurrent Asthma Management: Opportunities for a Nutrition-Based Intervention
Current Asthma Management: Opportunities for a Nutrition-Based Intervention Stanley J. Szefler, MD Approximately 22 million Americans, including 6 million children, have asthma. It is one of the most prevalent
More informationUtility of Exercise-Induced Zero TBI Sign in Patients on Maintenance Hemodialysis
2016 Annals of Vascular Diseases doi:10.3400/avd.oa.16-00074 Original Article Utility of Exercise-Induced Zero TBI Sign in Patients on Maintenance Hemodialysis Kazuo Tsuyuki, CVT, PhD, 1 Kenji Kohno, PhD,
More informationNephrology Unit- CHU Liège- Ulg- Belgium
Are the complications of arteriovenous fistulas associated with an abnormal Ankle-Brachial Index in Hemodialysis? A 4y study P. Xhignesse, A. Saint-Remy, B. Dubois, JC. Philips, JM. Krzesinski Nephrology
More information10/8/2018. Lecture 9. Cardiovascular Health. Lecture Heart 2. Cardiovascular Health 3. Stroke 4. Contributing Factor
Lecture 9 Cardiovascular Health 1 Lecture 9 1. Heart 2. Cardiovascular Health 3. Stroke 4. Contributing Factor 1 The Heart Muscular Pump The Heart Receives blood low pressure then increases the pressure
More informationCOPD in Korea. Division of Pulmonary, Allergy and Critical Care Medicine of Hallym University Medical Center Park Yong Bum
COPD in Korea Division of Pulmonary, Allergy and Critical Care Medicine of Hallym University Medical Center Park Yong Bum Mortality Rate 1970-2002, USA JAMA,2005 Global Burden of Disease: COPD WHO & World
More informationWales Primary Care COPD Audit
Wales Primary Care COPD Audit 2014-15 Next steps for improvement National Chronic Obstructive Pulmonary Disease (COPD) Audit Programme 2016 The audit programme partnership Working in strategic partnership:
More informationCircadian Variations Influential in Circulatory & Vascular Phenomena
SLEEP & STROKE 1 Circadian Variations Influential in Circulatory & Vascular Phenomena Endocrine secretions Thermo regulations Renal Functions Respiratory control Heart Rhythm Hematologic parameters Immune
More informationCoronary Artery Disease (CAD) Clinician Guide SEPTEMBER 2017
Kaiser Permanente National CLINICAL PRACTICE GUIDELINES Coronary Artery Disease (CAD) Clinician Guide SEPTEMBER 2017 Introduction This Clinician Guide is based on the 2017 KP National Coronary Artery Disease
More informationReferring for specialist respiratory input. Dr Melissa Heightman Consultant respiratory physician, UCLH,WH, CNWL
Referring for specialist respiratory input Dr Melissa Heightman Consultant respiratory physician, UCLH,WH, CNWL Respiratory Specialist- who? GPSI Community Team Secondary Care Respiratory physician and
More informationHypertriglyceridemia, Inflammation, & Pregnancy
Hypertriglyceridemia, Inflammation, & Pregnancy Richard L. Nemiroff, MD, FACOG, NLA Professor, Clinical Gynecology Perelman School of Medicine University of Pennsylvania Philadelphia, PA Disclosure of
More informationCOPD: Genomic Biomarker Status and Challenge Scoring
COPD: Genomic Biomarker Status and Challenge Scoring Julia Hoeng, PMI R&D Raquel Norel, IBM Research 3 rd October 2012 COPD: Genomic Biomarker Status Julia Hoeng, Ph.D. Philip Morris International, Research
More informationADULT ASTHMA GUIDE SUMMARY. This summary provides busy health professionals with key guidance for assessing and treating adult asthma.
ADULT ASTHMA GUIDE SUMMARY This summary provides busy health professionals with key guidance for assessing and treating adult asthma. Its source document Asthma and Respiratory Foundation NZ Adult Asthma
More informationTennessee Department of Health in collaboration with Tennessee State University and University of Tennessee Health Science Center
Tennessee Department of Health in collaboration with Tennessee State University and University of Tennessee Health Science Center 2006 Tennessee Department of Health 2006 ACKNOWLEDGEMENTS CONTRIBUTING
More informationAssociation between Airflow Obstruction and the Metabolic Syndrome or Its Components in Japanese Men
ORIGINAL ARTICLE Association between Airflow Obstruction and the Metabolic Syndrome or Its Components in Japanese Men Yayoi Funakoshi 1, Hisamitsu Omori 1, Shuichi Mihara 2, Tohru Marubayashi 2 and Takahiko
More informationCOPD. Breathing Made Easier
COPD Breathing Made Easier Catherine E. Cooke, PharmD, BCPS, PAHM Independent Consultant, PosiHleath Clinical Associate Professor, University of Maryland School of Pharmacy This program has been brought
More informationATHEROSCLEROSIS. Secondary changes are found in other coats of the vessel wall.
ATHEROSCLEROSIS Atherosclerosis Atherosclerosis is a disease process affecting the intima of the aorta and large and medium arteries, taking the form of focal thickening or plaques of fibrous tissue and
More informationCOMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP)
European Medicines Agency Pre-Authorisation Evaluation of Medicines for Human Use London, 19 February 2009 Doc. Ref. EMEA/CHMP/EWP/8197/2009 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) CONCEPT
More informationChronic Obstructive Pulmonary Disease
Chronic Obstructive Pulmonary Disease 07 Contributor Dr David Tan Hsien Yung Definition, Diagnosis and Risk Factors for (COPD) Differential Diagnoses Goals of Management Management of COPD THERAPY AT EACH
More information